Diskussion zur BICO Group Aktie WKN: A2PX00 ISIN: SE0013647385 Forum: Aktien User: Hedgehog3
OCTOBER – DECEMBER 2022 (COMPARED WITH OCTOBER – DECEMBER 2021) Net sales amounted to SEK 674.1 million (519.1), which corresponds to an increase of 30% (151) compared to the corresponding quarter previous year. Organic revenue growth for the quarter amounted to 8% (25). EBITDA amounted to SEK 24.3 million (13.0), corresponding to a margin of 3.6% (2.5). Adjusted EBITDA amounted to SEK 26.9 million (24.1), corresponding to a margin of 4.0% (4.6). Net profit/loss for the quarter amounted to SEK -901.8 million (-25.9), corresponding to earnings per share before and after dilution of SEK -13.73 (-0.41). This was affected by goodwill impairment of Ginolis amounting to SEK 625.0 million. The gross margin amounted to 71.6% (72.3). JANUARY – DECEMBER 2022 (COMPARED WITH JANUARY – DECEMBER 2021) Net sales amounted to SEK 2,239.5 million (1,257.3), which corresponds to an increase of 78% (244) compared to the corresponding period previous year. Organic growth for the period amounted to 17% (44). EBITDA amounted to SEK -56.3 million (-45.1), corresponding to a margin of -2.5% (-3.6). Adjusted EBITDA amounted to SEK 62.1 million (16.9), corresponding to a margin of 2.8% (1.3). Net profit/loss for the period amounted to SEK -835.7million (-229.2), corresponding to earnings per share before and after dilution of SEK -12.94 (-3.97). This was affected by impairment of Ginolis amounting to SEK 625.0 million. The gross margin amounted to 73.6% (72.2). Strategic collaboration with Sartorius, resulting in commercial opportunities and a strengthened balance sheet. The Board proposes no dividend for 2022. “We remain focused on executing our business plan for profitable growth and improved cash flow.” Erik Gatenholm, President & CEO BICO Group AB Q4 KEY TAKEAWAYS SEK 487 million directed share issue to Sartorius All-time high revenue Continued improvements on profitability and cash flow Continued focus on operational efficiency and portfolio synergies Cost savings program on target Impairment of goodwill in Ginolis 10 NOVEMBER 2022 BICO ANNOUNCED NEW FINANCIAL TARGETS FROM 2023: Double-digit organic revenue growth in constant currency EBITDA Margin less capitalized development cost > 10% NET DEBT / EBITDA <3.0x.
Mehr zu diesem Wert
|
Thema | ||
---|---|---|---|
1 | Trading- und Aktien-Chat | ||
2 | für alle, die es ehrlich meinen beim Traden. | ||
3 | GAMESTOP Hauptdiskussion | -0,55 % | |
4 | BLOOM ENERGY A Hauptdiskussion | -0,75 % | |
5 | Das neue Dax Prognose Forum | +0,09 % | |
6 | VITAL THERAPIES Hauptdiskussion | -0,99 % | |
7 | MicroStrategy | -0,43 % | |
8 | MODERNA INC. DL-,0001 Hauptdiskussion | -0,62 % | |
9 | Lilium Aktie | -42,62 % | |
10 | BED BATH & BEYOND Hauptdiskussion | ±0,00 % | Alle Diskussionen |
|
Thema | ||
---|---|---|---|
1 | BLOOM ENERGY A Hauptdiskussion | -0,75 % | |
2 | GAMESTOP Hauptdiskussion | -0,55 % | |
3 | VITAL THERAPIES Hauptdiskussion | -0,99 % | |
4 | Lilium Aktie | -42,62 % | |
5 | BED BATH & BEYOND Hauptdiskussion | ±0,00 % | |
6 | MODERNA INC. DL-,0001 Hauptdiskussion | -0,62 % | |
7 | MicroStrategy | -0,43 % | |
8 | BAYER Hauptdiskussion | ±0,00 % | |
9 | ASML HOLDING Hauptdiskussion | ±0,00 % | |
10 | EVOTEC Hauptdiskussion | ±0,00 % | Alle Diskussionen |